TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00093613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02481635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Study: NCT00650858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
Description: 0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
Description: 0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
Description: 0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
Study: NCT02630953

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original Tailored Intervention
Description: The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Tailored Intervention
Description: Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
Study: NCT01154647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 ml 0.9 % NaCl
Description: intravenous
Study: NCT02385279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent
Description: Percutaneous Coronary Intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE EES
Description: Percutaneous Coronary Intervention
Study: NCT01961115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MELITAC 12.1 Peptide Vaccine
Description: Given ID/SC
Study: NCT01021189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution Dose single and followed by 7-day multiple dosing.
Study: NCT00559078

Intervention type: OTHER
Intervention: Interview
Description: Hour-long, qualitative, phone interview
Study: NCT02111044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: octreotide 100 mcg sc t.i.d. for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 500 mcg
Description: ITF2984 500 mcg sc b.i.d for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 1000 mcg
Description: ITF2984 1000 mcg sc b.i.d for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 2000 mcg
Description: ITF2984 2000 mcg sc b.i.d for 4 weeks
Study: NCT04415398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated flying Drone carrying an Automated external defibrillator (AED)
Description: Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
Study: NCT02926703

Intervention type: OTHER
Intervention: Serum lactate and CK concentrations in blood samples
Description: Serum lactate and CK concentrations in blood samples were measured routinely at admission

Intervention type: OTHER
Intervention: Serum lactate and CK concentrations in blood samples
Description: Serum lactate and CK concentrations in blood samples were measured routinely at admission
Study: NCT02670603

Intervention type: DRUG
Group type: OTHER
Intervention: EVONAIL® solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVONAIL® solution
Study: NCT03529409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Khanya
Description: This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
Study: NCT00933036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosstrees Pod system for PVA
Description: Minimally invasive spine surgery
Study: NCT01011348

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months
Study: NCT00867880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIb
Description: 800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIb
Description: 800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
Study: NCT04243668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)
Description: In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire.
Study: NCT00404313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0633
Description: Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
Study: NCT01011348

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months
Study: NCT00404313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0633
Description: Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0633
Description: Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
Study: NCT01011348

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period
Study: NCT04235374

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FFC-AC-EIT
Description: The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FFC-AC-EIT
Description: The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.
Study: NCT01291602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL104
Description: IV Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ104
Description: IV Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline
Study: NCT00404313

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
Study: NCT04002986

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: A blood draw or saliva kit will be provided to collect subject cells
Study: NCT00931424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: valve reconstruction
Description: reconstruct valve at the same time of superficial vein surgery
Study: NCT01453231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thighplasty
Description: Plastic surgery of thigh
Study: NCT01651780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: Unfractionated heparin is an anticoagulant.
Study: NCT01755663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine and Metoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine and Metoprolol
Study: NCT01207830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo Bypass System
Description: Subject is implanted with the device for up to 3 years.
Study: NCT01422993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 Week Exercise Program
Description: Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
Study: NCT02347904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 and Oxaliplatin
Description: Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
Study: NCT03725553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramyometrial Vasopressin
Description: a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
Study: NCT01017250

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
Study: NCT03894345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
Study: NCT04524845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unloading brace
Description: Participants underwent one session of gait analysis. The experimental protocol was divided in four conditions, the control condition without brace (NO), and then three conditions with the different braces tested in a randomized order.~For each condition, the participant was fitted with the brace by the same experimenter and equipped with 19/20 retro-reflective markers (without/with brace) on the pelvis and the investigated leg for motion analysis. After a short recording in a fixed standing position (static trial), each participant carried out at least three barefoot walking trials of a few meters long at a self-selected pace. The walking trial was validated if a complete gait cycle occurred on the two 90cm x 90 cm force plates recording the ground reaction forces. After each condition, the participant had to assess knee pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebel Reliever (RR)
Description: Rebel Reliever (RR) (Thuasne, Levallois Perret, France)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action Reliever
Description: Action Reliever (AR) (Thuasne, Levallois Perret, France)
Study: NCT02489318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo orally once daily in each 28 day treatment cycles.
Study: NCT02368548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care Program
Description: Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
Study: NCT03084133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education Strategy
Description: In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002).
Study: NCT03316352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted paramedian technique spinal anesthesia
Description: Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
Study: NCT02489318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Study: NCT01612923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midwife
Description: gynecological exam and ultrasound and contraceptive advice provided by midwife
Study: NCT02834754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
Study: NCT00439738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ + Amlodipine
Description: * 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules~* 5 mg amlodipine capsules~* 10 mg amlodipine capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ
Description: * 160 mg film-coated valsartan tablets~* 320 mg film-coated valsartan tablets~* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules
Study: NCT04411563

Intervention type: OTHER
Intervention: Taking biological samples
Description: Taking blood samples for biochemical and epigenetic analysis

Intervention type: OTHER
Intervention: Taking biological samples
Description: Taking blood samples for biochemical and epigenetic analysis

Intervention type: OTHER
Intervention: Taking biological samples
Description: Taking blood samples for biochemical and epigenetic analysis
Study: NCT03316352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-guided paramedian technique spinal anesthesia
Description: Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% heavy bupivacaine
Description: During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine
Description: During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
Study: NCT02813772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk formula NAN Sensitive, Nestle
Description: Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk formula Optipro, Nestle
Description: Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
Study: NCT04058522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator cuff rehabilitation classes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Physiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Injection
Description: Subacromial Injection 40mg/1ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection
Description: Subacromial Injection 40mg/1ml
Study: NCT02269358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METHOTREXATE
Description: Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
Study: NCT01468987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro